Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05522075

Reducing Blood Pressure in Mid-life Adult Binge Drinkers

Reducing Blood Pressure in Mid-life Adult Binge Drinkers: the Role of Microvascular Function and Sympathetic Activity

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
55 (estimated)
Sponsor
The University of Texas at Arlington · Academic / Other
Sex
All
Age
50 Years – 64 Years
Healthy volunteers
Accepted

Summary

This study has two phases: Phase 1 is to examine blood pressure, microvascular function, and sympathetic nerve activity in mid-life adult binge drinkers vs. alcohol abstainers/moderate drinkers. Phase 2 is to examine the effect of 8-week aerobic exercise training on blood pressure, microvascular function, and sympathetic nerve activity in mid-life adult binge drinkers

Detailed description

During phase 1, we will measure blood pressure, microvascular function, and sympathetic nerve activity (baseline assessment) in mid-life adult binge drinkers, alcohol abstainers, and moderate drinkers. Only mid-life adult binge drinkers will enter Phase 2 and be randomized to the exercise training group and non-exercise control group. After 8 weeks of intervention, we will re-measure blood pressure, microvascular function, and sympathetic nerve activity (post-intervention assessment) in mid-life adult binge drinkers.

Conditions

Interventions

TypeNameDescription
BEHAVIORALExercise TrainingSubjects will be asked to perform exercise training (high-intensity interval training) under supervision, 3 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
BEHAVIORALAlcohol Abstinence InterventionSubjects will be asked to abstain from alcohol for 8 weeks. Education materials and bi-weekly consultations will be provided.

Timeline

Start date
2022-11-21
Primary completion
2026-04-30
Completion
2026-04-30
First posted
2022-08-30
Last updated
2026-02-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05522075. Inclusion in this directory is not an endorsement.